by Elena Iemma | Feb 27, 2025 | News
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements PROVIDENCE, R.I., Feb. 27, 2025 — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and...
by Elena Iemma | Dec 9, 2024 | News
PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth....
by Elena Iemma | Mar 29, 2024 | News
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ — Read the publication. In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk –...
by Elena Iemma | Dec 20, 2023 | News
PROVIDENCE, RI, December 20, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for immunogenicity risk assessment of...
by Elena Iemma | May 17, 2023 | News
PROVIDENCE, RI, May 17, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company. In addition,...
